Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Darcy

Showing results (91-100 of 222) with videos related to

Pageof 23
Sort By:
Cancer Research|March 22, 2003
Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group studyJohn Farley, Leia M Smith, Kathleen M Darcy, et al.
Acta Obstetricia Et Gynecologica Scandinavica|March 5, 2021
A prognostic system for epithelial ovarian carcinomas using machine learningPhilip M Grimley, Zhenqiu Liu, Kathleen M Darcy, et al.
Journal of Technology in Behavioral Science|October 31, 2018
The Utility and Acceptability of a Self-Help Smartphone Application for Eating Disorder BehaviorsJane Paik Kim, Shiri Sadeh-Sharvit, Alison M Darcy, et al.
Eating Disorders|February 17, 2018
Subgrouping the users of a specialized app for eating disordersShiri Sadeh-Sharvit, Jane Paik Kim, Alison M Darcy, et al.
Oncogene|September 22, 2010
Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancerX He, A D Arslan, M D Pool, et al.
Eating Disorders|April 11, 2017
A qualitative analysis of male eating disorder symptomsKatherine D Arnow, Talya Feldman, Elizabeth Fichtel, et al.
Gynecologic Oncology|March 23, 2006
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study, Angeles Alvarez Secord, Paula S Lee, et al.
Gynecologic Oncology|February 22, 2005
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group studyAgustin A Garcia, John A Blessing, Heinz-Josef Lenz, et al.
Gynecologic Oncology|February 20, 2007
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Doris Benbrook, et al.
Gynecologic Oncology Reports|February 16, 2022
Increasing incidence of uterine carcinosarcoma: A United States Cancer Statistics studyCheng-I Liao, Michelle Ann Caesar, Danny Lee, et al.
Pageof 23

Showing results (91-100 of 222) with videos related to

Sort By:
Pageof 23
Cancer Research|March 22, 2003
Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group studyJohn Farley, Leia M Smith, Kathleen M Darcy, et al.
Acta Obstetricia Et Gynecologica Scandinavica|March 5, 2021
A prognostic system for epithelial ovarian carcinomas using machine learningPhilip M Grimley, Zhenqiu Liu, Kathleen M Darcy, et al.
Journal of Technology in Behavioral Science|October 31, 2018
The Utility and Acceptability of a Self-Help Smartphone Application for Eating Disorder BehaviorsJane Paik Kim, Shiri Sadeh-Sharvit, Alison M Darcy, et al.
Eating Disorders|February 17, 2018
Subgrouping the users of a specialized app for eating disordersShiri Sadeh-Sharvit, Jane Paik Kim, Alison M Darcy, et al.
Oncogene|September 22, 2010
Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancerX He, A D Arslan, M D Pool, et al.
Eating Disorders|April 11, 2017
A qualitative analysis of male eating disorder symptomsKatherine D Arnow, Talya Feldman, Elizabeth Fichtel, et al.
Gynecologic Oncology|March 23, 2006
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study, Angeles Alvarez Secord, Paula S Lee, et al.
Gynecologic Oncology|February 22, 2005
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group studyAgustin A Garcia, John A Blessing, Heinz-Josef Lenz, et al.
Gynecologic Oncology|February 20, 2007
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Doris Benbrook, et al.
Gynecologic Oncology Reports|February 16, 2022
Increasing incidence of uterine carcinosarcoma: A United States Cancer Statistics studyCheng-I Liao, Michelle Ann Caesar, Danny Lee, et al.
Pageof 23